Strategies for managing an outsourcing partner
Robust oversight linked to increased efficiency and better communication with outsourcing partners.
The healthcare industry has undergone a transformation over the last few decades, with an uptick in outsourcing shining through as a key trend. The benefits of outsourcing research, development or manufacturing activities are multifold – it can cut R&D costs, increase efficiency across the value chain, and allows companies to benefit from expertise they may lack in-house.
However, engaging an outsourcing partner such as a CRO or CDMO comes with its risks. According to Stephanie Gaulding, Managing Director at Pharmatech Associates, the more hands-off approach a sponsor takes, the higher the risk becomes.
Gaulding led a session on strategies for managing outsourcing partners at CPHI North America this week and emphasised the importance of creating a robust oversight framework.
‘You need to have processes in place to control quality and oversee your outsource activities,’ she told conference attendees.
‘Without these processes you can run the risk of things going awry - not having adequate oversight, not making sure that products are made in accordance with the associated regulations.’
Gaulding recommended defining activities that can be delegated early in the process, and clearly outlining these in contractual documents.
She added that the level of oversight a sponsor retains is a crucial consideration – too little can lead to delays and miscommunication, while micromanagement can result in inefficiencies.
She said: ‘What we ultimately want to do is stay in that middle range, where we have tailored oversight that is tweaked and adjusted per the conditions that you’re dealing with. That’s going to get you to optimal efficiency, that’s going to get to robust communication.’
Gaulding encouraged sponsors to create detailed oversight plans, which includes everything about the scope and nature of the engagement with the outsourcing partner. She noted that gaining familiarity with an outsourcing partner’s internal processes and systems can pay dividends, so that requirements imposed on them are manageable and more likely to result in success.
‘I’d encourage everybody to understand your partner’s processes really well, go into it with an open mind and only make adjustments where you absolutely think there needs to be an adjustment,’ she said. ‘Because you’re going to cause them to trip over themselves trying to remember all these additional requirements.’
Gaulding also advised assessing a partner’s risk points, mitigating these where possible, and enacting a change management plan.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Eli Lilly confirms Pennsylvania for US$3.5bn manufacturing site
The company plans to create more than 2,800 manufacturing and construction jobs at Lilly's 10th US manufacturing site announced since 2020.
-
News Drug Approvals from 2025 – Triumphs in the midst of challenges
The following infographic outlines key drugs that have been newly approved by the US FDA in 2025. -
News Johnson & Johnson completes acquisition of Halda Therapeutics
Acquisition brings an advanced, highly differentiated treatment for prostate cancer, strengthening Johnson & Johnson’s longstanding commitment to innovation in the disease. Lead asset demonstrates potential to overcome key resistance pathways ... -
News AI-powered therapy offers hope for rare familial polyposis
Recursion Pharmaceuticals has announced promising results from its ongoing early- to mid-stage trial evaluating its AI-powered treatment, REC-4881, for familial adenomatous polyposis (FAP).
-
News CPHI Podcast Series: From Patents to Public Health: The GLP-1 Journey
The latest episode of the CPHI Podcast Series delves into the future of obesity management globally, offering opinins on might happen after patent expirys and new globals players entering the fray.
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta...